Consenso colombiano para el diagnóstico y tratamiento de la esofagitis eosinofílica en población pediátrica: el tratamiento. Parte 2
DOI:
https://doi.org/10.22516/25007440.1408Palavras-chave:
Esofagitis eosinofílica, endoscopia, biopsia, dietoterapia, inhibidores de la bomba de protones, budesonida, medicamentos biológicosResumo
Introducción: la esofagitis eosinofílica (EoE) es una enfermedad crónica inmunomediada caracterizada por disfunción esofágica, que puede llevar a fibrosis o estenosis de no recibir tratamiento.
Objetivo: desarrollar recomendaciones basadas en la evidencia por un consenso de expertos para el tratamiento de la EoE en <18 años.
Metodología: un panel multidisciplinario de 16 expertos del Colegio Colombiano de Gastroenterología, Hepatología y Nutrición Pediátrica (COLGAHNP), alergólogos, patólogos y gastroenterólogos de adultos, junto con cuatro expertos internacionales formularon 18 preguntas (8 de diagnóstico y 10 de tratamiento). Mediante una búsqueda de la literatura, se analizaron guías de práctica clínica (GPC), estudios clínicos aleatorizados (ECA) y revisiones sistemáticas de la literatura (RSL) de los últimos 10 años. Se desarrollaron 27 recomendaciones (12 de diagnóstico y 15 de tratamiento), que fueron sometidas a votación por el método Delphi modificado en dos votaciones. El estudio fue patrocinado por el COLGAHNP.
Resultados: las recomendaciones alcanzaron un acuerdo >90%. El tratamiento debe ser individualizado y multidisciplinario, liderado por gastroenterólogos pediatras. El tratamiento se basa en dieta de eliminación “ascendente”, iniciando con un solo alimento, uso de inhibidores de la bomba de protones, esteroides tópicos, anticuerpos monoclonales y, en algunos casos, dilatación. En el seguimiento se deben usar herramientas validadas, como el PEEESv2. Se deben preparar a los pacientes para la transición a la edad adulta.
Conclusión: se proporciona un consenso con recomendaciones basadas en la evidencia sobre el tratamiento de la EoE para pacientes, familiares y aseguradores en el contexto colombiano y latinoamericano.
Downloads
Referências
Hirano I. How to Approach a Patient With Eosinophilic Esophagitis. Gastroenterology. 2018;155(3):601-6. https://doi.org/10.1053/j.gastro.2018.08.001
Chan J, Flynn DM, Gordon M, Parmar R, Moolenschot K, Jackman L, et al. Swallowed topical steroid therapy for eosinophilic oesophagitis in children: practical, evidence-based guidance by the BSPGHAN Eosinophilic Oesophagitis Working Group. BMJ Paediatr Open. 2024;8(1):e002467-e002467. https://doi.org/10.1136/bmjpo-2023-002467
de Bortoli N, Visaggi P, Penagini R, Annibale B, Baiano Svizzero F, Barbara G, et al. The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis - Definition, Clinical Presentation and Diagnosis. Dig Liver Dis. 2024;56(6):951-63. https://doi.org/10.1016/j.dld.2024.02.005
Amil-Dias J, Oliva S, Papadopoulou A, Thomson M, Gutiérrez-Junquera C, Kalach N, et al. Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2024;79(2):394-437. https://doi.org/10.1002/jpn3.12188
Arias Á, Tejera-Muñoz A, Gutiérrez-Ramírez L, Molina-Infante J, Lucendo AJ. Efficacy of Dietary Therapy for Eosinophilic Esophagitis in Children and Adults: An Updated Systematic Review and Meta-Analysis. Nutrients. 2024;16(14):2231. https://doi.org/10.3390/nu16142231
Franciosi JP, Gordon M, Sinopoulou V, Dellon ES, Gupta SK, Reed CC, et al. Medical treatment of eosinophilic esophagitis. Cochrane Database Syst Rev. 2023;2023(7):CD004065. https://doi.org/10.1002/14651858.CD004065.pub4
Dhar A, Haboubi HN, Attwood SE, Auth MKH, Dunn JM, Sweis R, et al. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut. 2022;71(8):1459-87. https://doi.org/10.1136/gutjnl-2022-327326
Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the U.S. preventive services task force: A review of the process. Am J Prev Med. 2001;20(3 Suppl):21-35. https://doi.org/10.1016/S0749-3797(01)00261-6
Harris PR, Calderón-Guerrero OG, Vera-Chamorro JF, Lucero Y, Vásquez M, Kazuo Ogata S, et al. Adaptación a la realidad de Latinoamérica de la Guía Clínica NASPGHAN/ESPGHAN 2016 sobre Diagnóstico, Prevención y Tratamiento de Infección por Helicobacter pylori en Pediatría. Rev Chil pediatría. 2020;91(5):809-27. https://doi.org/10.32641/rchped.v91i5.2579
Kliewer KL, Abonia JP, Aceves SS, Atkins D, Bonis PA, Capocelli KE, et al. One-food versus 4-food elimination diet for pediatric eosinophilic esophagitis: A multisite randomized trial. J Allergy Clin Immunol. 2025;155(2):520-532. https://doi.org/10.1016/j.jaci.2024.08.023
Chahuan J, Lucendo AJ. Dietary Treatment for Children and Adults with Eosinophilic Esophagitis: Which Patient and Which Doctor Is It Suitable for? Inflamm Intest Dis. 2024;9(1):184-98. https://doi.org/10.1159/000540228
Lim AHW, Ngoi B, Perkins GB, Wong S, Whitelock G, Hurtado P, et al. Outcomes of Serum Food-Specific Immunoglobulin G 4 to Guide Elimination Diet in Patients With Eosinophilic Esophagitis. Am J Gastroenterol. 2024;119(6):1066-73. https://doi.org/10.14309/ajg.0000000000002678
Visaggi P, Ghisa M, Barberio B, Maniero D, Greco E, Savarino V, et al. Treatment Trends for Eosinophilic Esophagitis and the Other Eosinophilic Gastrointestinal Diseases: Systematic Review of Clinical Trials. Dig Liver Dis. 2023;55(2):208-22. https://doi.org/10.1016/j.dld.2022.05.004
Visaggi P, Baiano Svizzero F, Savarino E. Food elimination diets in eosinophilic esophagitis: Practical tips in current management and future directions. Best Pract Res Clin Gastroenterol. 2023;62-63:101825. https://doi.org/10.1016/j.bpg.2023.101825
Chang JW, Kliewer K, Haller E, Lynett A, Doerfler B, Katzka DA, et al. Development of a Practical Guide to Implement and Monitor Diet Therapy for Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2023;21(7):1690-8. https://doi.org/10.1016/j.cgh.2023.03.006
Jacobse J, Brown R, Revetta F, Vaezi M, Buendia MA, Williams CS, et al. A synthesis and subgroup analysis of the eosinophilic esophagitis tissue transcriptome. J Allergy Clin Immunol. 2024;153(3):759-71. https://doi.org/10.1016/j.jaci.2023.10.002
Votto M, De Filippo M, Lenti MV, Rossi CM, Di Sabatino A, Marseglia GL, et al. Diet Therapy in Eosinophilic Esophagitis. Focus on a Personalized Approach. Front Pediatr. 2022;9:820192. https://doi.org/10.3389/fped.2021.820192
Kliewer KL, Gonsalves N, Dellon ES, Katzka DA, Abonia JP, Aceves SS, et al. One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial. lancet Gastroenterol Hepatol. 2023;8(5):408-21. https://doi.org/10.1016/S2468-1253(23)00012-2
Wechsler JB, Schwartz S, Arva NC, Kim KYA, Chen L, Makhija M, et al. A Single-Food Milk Elimination Diet Is Effective for Treatment of Eosinophilic Esophagitis in Children. Clin Gastroenterol Hepatol. 2022;20(8):1748-1756.e11. https://doi.org/10.1016/j.cgh.2021.03.049
Pitsios C, Vassilopoulou E, Pantavou K, Terreehorst I, Nowak-Wegzryn A, Cianferoni A, et al. Allergy-Test-Based Elimination Diets for the Treatment of Eosinophilic Esophagitis: A Systematic Review of Their Efficacy. J Clin Med. 2022;11(19):5631. https://doi.org/10.3390/jcm11195631
Mayerhofer C, Kavallar AM, Aldrian D, Lindner AK, Müller T, Vogel GF. Efficacy of Elimination Diets in Eosinophilic Esophagitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21(9):2197-2210.e3. https://doi.org/10.1016/j.cgh.2023.01.019
Munoz-Persy M, Lucendo AJ. Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach. Eur J Pediatr 2018 1775. 2018;177(5):649-63. https://doi.org/10.1007/s00431-018-3129-7
Shah SC, Tepler A, Peek RM, Colombel JF, Hirano I, Narula N. Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis-A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019;17(11):2185-2198.e3. https://doi.org/10.1016/j.cgh.2019.01.013
Hiramoto B, Muftah M, Flanagan R, Shah ED, Chan WW. Cost-Effectiveness Analysis of Current Treatment Options for Eosinophilic Esophagitis. Am J Gastroenterol. 2025;120(1):161-172. https://doi.org/10.14309/ajg.0000000000003104
Gutiérrez Junquera C, Fernández Fernández S, Domínguez-Ortega G, Vila Miravet V, García Puig R, García Romero R, et al. Recomendaciones para el diagnóstico y manejo práctico de la esofagitis eosinofílica pediátrica. An Pediatría. 2020;92(6):376.e1-376.e10. https://doi.org/10.1016/j.anpedi.2020.04.007
Gautam R, Lal M, Carroll MC, Mrozek Z, Trachsel T, Beers J, et al. Proton pump inhibitors modulate esophageal epithelial barrier function and crosstalk with eosinophils. bioRxiv [Preprint]. 2024:2024.08.22.609219. https://doi.org/10.1101/2024.08.22.609219
Laserna-Mendieta EJ, Casabona S, Guagnozzi D, Savarino E, Perelló A, Guardiola-Arévalo A, et al. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. Aliment Pharmacol Ther. 2020;52(5):798-807. https://doi.org/10.1111/apt.15957
Rodríguez López AE. Análisis de respuesta a tratamiento con inhibidores de bomba de protones en pacientes pediátricos con esofagitis eosinofílica en Bogotá, Colombia. Universidad de Los Andes; 2023.
Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2016;14(1):13-22.e1. https://doi.org/10.1016/j.cgh.2015.07.041
Schoepfer AM, Safroneeva E. Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs. Inflamm Intest Dis. 2024;9(1):199-209. https://doi.org/10.1159/000540275
Mougey EB, Williams A, Kunz Coyne AJ, Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, et al. CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2019;69(5):581-7. https://doi.org/10.1097/MPG.0000000000002480
Chevalier R, Attard T, Van Driest SL, Shakhnovich V. A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens. Expert Opin Drug Metab Toxicol. 2023;19(2):53-6. https://doi.org/10.1080/17425255.2023.2190883
Bose P, Kumar S, Nebesio TD, Li C, Hon EC, Atkins D, et al. Adrenal Insufficiency in Children With Eosinophilic Esophagitis Treated With Topical Corticosteroids. J Pediatr Gastroenterol Nutr. 2020;70(3):324-9. https://doi.org/10.1097/MPG.0000000000002537
Philpott H, Dougherty MK, Reed CC, Caldwell M, Kirk D, Torpy DJ, et al. Systematic review: adrenal insufficiency secondary to swallowed topical corticosteroids in eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018;47(8):1071-8. https://doi.org/10.1111/apt.14573
McCallen JD, Dave M, LaFata SS, Cameron BA, Xue AZ, Kiran A, et al. Topical Steroids Are Effective and Safe in Patients With Eosinophilic Esophagitis Over a Median of 6.5 Years of Chronic Use. J Clin Gastroenterol. 2025;59(8):737-743. https://doi.org/10.1097/MCG.0000000000002081
Rubinstein E, Hait EE, Mitchell PD, Lee JJ. Every-other-day Dosing of Oral Viscous Budesonide Is not Effective in the Management of Eosinophlic Esophagitis. J Pediatr Gastroenterol Nutr. 2018;66(3):395-7. https://doi.org/10.1097/MPG.0000000000001718
Russin M, Chen J, Rubenstein JH, Chang JW. Real-World Effectiveness and Use of Dupilumab in Eosinophilic Esophagitis. Am J Gastroenterol. 2025;120(3):663-666. https://doi.org/10.14309/ajg.0000000000003087
Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024;390(24):2239-51. https://doi.org/10.1056/NEJMoa2312282
Sanofi. Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) [Internet]. Sanofi; 2024 [consultado el 12 de julio de 2024]. Disponible en: https://www.sanofi.com/en/media-room/press-releases/2024/2024-01-25-19-30-00-2817342
Aceves SS, Dellon ES, Greenhawt M, Hirano I, Liacouras CA, Spergel JM. Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick. Ann Allergy Asthma Immunol. 2023;130(3):371-8. https://doi.org/10.1016/j.anai.2022.12.014
Sanofi. How DUPIXENT® (dupilumab) is Taken: EoE Dosing [Internet]. Sanofi; 2024 [consultado el 12 de julio de 2024]. Disponible en: https://www.dupixent.com/eoe/about-dupixent/how-dupixent-is-taken
Agencia Española de Medicamentos y Productos Sanitarios, Comité de Evaluación de Nuevos Medicamentos en el Ámbito Hospitalario de Euskadi, Comunidad Autónoma de Andalucía, Programa de Armonización Farmacoterapéutica del Servicio Catalán de la Salud. Informe de Posicionamiento Terapéutico de dupilumab en asma grave no controlada [Internet]. AEMPS; 2022 [consultado el 15 de julio de 2024]. Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/2022/IPT_04-2022-dupilumab.pdf
Kuhn BR, Chittoor G, Johns A, Berger A, Justice AE. Patient reported data integration for management of Eosinophilic Esophagitis. Dis Esophagus. 2022;35(10):doac012. https://doi.org/10.1093/dote/doac012
Aceves SS, King E, Collins MH, Yang GY, Capocelli KE, Abonia JP, et al. Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. J Allergy Clin Immunol. 2018;142(1):130-138.e1. https://doi.org/10.1016/j.jaci.2018.05.014
Ilia S, Monica V, Daniel S. Mean nocturnal baseline impedance and endoscopic mucosal impedance measurements in patients with eosinophilic esophagitis: a new tool for follow up and management? Updates Surg. 2023;75(2):389-93. https://doi.org/10.1007/s13304-022-01331-4
Primo J, Tankosich G, Critelli K, Sinclair E. Barriers to treatment adherence in pediatric eosinophilic esophagitis. JPGN Reports. 2025;6(3):241-247. https://doi.org/10.1002/jpr3.70031
Case C, Furuta GT, Atkins D, Pan Z, Robinson J. Diet and stress in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2017;65(3):281-284. https://doi.org/10.1097/MPG.0000000000001481
Al-Hussaini A. Savary Dilation Is Safe and Effective Treatment for Esophageal Narrowing Related to Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2016;63(5):474-80. https://doi.org/10.1097/MPG.0000000000001247
Schoepfer AM, Safroneeva E, Bussmann C, Kuchen T, Portmann S, Simon HU, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145(6):1230-1236.e2. https://doi.org/10.1053/j.gastro.2013.08.015
Singla MB, Chehade M, Brizuela D, Maydonovitch CL, Chen YJ, Riffle ME, et al. Early Comparison of Inflammatory vs. Fibrostenotic Phenotype in Eosinophilic Esophagitis in a Multicenter Longitudinal Study. Clin Transl Gastroenterol. 2015;6(12):e132. https://doi.org/10.1038/ctg.2015.62
Wolf WA, Cotton CC, Green DJ, Hughes JT, Woosley JT, Shaheen NJ, et al. Predictors of Response to Steroid Therapy for Eosinophilic Esophagitis and Treatment of Steroid-Refractory Patients. Clin Gastroenterol Hepatol. 2014;13(3):452- 8. https://doi.org/10.1016/j.cgh.2014.07.034
Wang L, Mara KC, Ravi K, Wu TT, Smyrk TC, Katzka DA, et al. Predictors of histologic response to dietary therapy in eosinophilic oesophagitis. Aliment Pharmacol Ther. 2022;56(10):1444-52. https://doi.org/10.1111/apt.17221
Shahein AR, Krasaelap A, Ng K, Bitton S, Khan M, Manfredi MA, et al. Esophageal Dilation in Children: A State of the Art Review. J Pediatr Gastroenterol Nutr. 2023;76(1):1-8. https://doi.org/10.1097/MPG.0000000000003614
Hoofien A, Rea F, Espinheira M do C, Amil Dias J, Romano C, Oliva S, et al. Systemic steroids have a role in treating esophageal strictures in pediatric eosinophilic esophagitis. Dig Liver Dis. 2021;53(3):324-8. https://doi.org/10.1016/j.dld.2020.11.025
Kavitt RT, Ates F, Slaughter JC, Higginbotham T, Shepherd BD, Sumner EL, et al. Randomized controlled trial comparing esophageal dilation to no dilation among adults with esophageal eosinophilia and dysphagia. Dis esophagus Off J Int Soc Dis Esophagus. 2016;29(8):983-91. https://doi.org/10.1111/dote.12398
Dellon ES, Kim HP, Sperry SLW, Rybnicek DA, Woosley JT, Shaheen NJ. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79(4):577-85.e4. https://doi.org/10.1016/j.gie.2013.10.027
Moawad FJ, Molina-Infante J, Lucendo AJ, Cantrell SE, Tmanova L, Douglas KM. Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46(2):96-105. https://doi.org/10.1111/apt.14123
Lipka S, Kumar A, Richter JE. Successful Esophageal Dilation of Eosinophilic Esophagitis (EoE) Patients With a Previous Postdilation Complication: Start Low and Go Slow. J Clin Gastroenterol. 2018;52(9):773-7. https://doi.org/10.1097/MCG.0000000000000873
Eluri S, Tappata M, Huang KZ, Koutlas NT, Robey BS, Fan C, et al. Distal esophagus is the most commonly involved site for strictures in patients with eosinophilic esophagitis. Dis esophagus Off J Int Soc Dis Esophagus. 2020;33(2): doz088. https://doi.org/10.1093/dote/doz088
Hoskins B, Almazan E, Hohl B, Ng K. Esophageal dilation with EsoFLIP is faster than CRE balloon dilation combined with EndoFLIP in children. Surg Endosc. 2023;37(8):6308-14. https://doi.org/10.1007/s00464-023-10129-3
Richter JE. Esophageal dilation for eosinophilic esophagitis: it’s safe! Why aren’t we doing more dilations? Gastrointest Endosc. 2017;86(4):592-4. https://doi.org/10.1016/j.gie.2017.05.019
van Klink ML, Bredenoord AJ. Health-Related Quality of Life in Patients with Eosinophilic Esophagitis. Immunol Allergy Clin North Am. 2024;44(2):265-80. https://doi.org/10.1016/j.iac.2023.12.011
Garcia-Martinez de Bartolomé R, Barrio-Torres J, Cilleruelo-Pascual MlL, Rodríguez-Soler JJ, Gil-de Miguel Á, Sebastián-Viana T. Psychometric evaluation of the Spanish version of the Pediatric Quality of Life Eosinophilic Esophagitis Questionnaire (Peds QL-EoE Module TM). Health Qual Life Outcomes. 2023;21(1):133. https://doi.org/10.1186/s12955-023-02211-0
Franciosi JP, Hommel KA, Bendo CB, King EC, Collins MH, Eby MD, et al. PedsQL eosinophilic esophagitis module: feasibility, reliability, and validity. J Pediatr Gastroenterol Nutr. 2013;57(1):57-66. https://doi.org/10.1097/MPG.0b013e31828f1fd2
Jensen ET, Chaiboonma K, Ayala O, Proia A, Aceves SS. Sleep, Anxiety, Somatization, Quality of Life, and Resilience in Pediatric Patients With Eosinophilic Esophagitis. Clin Transl Gastroenterol. 2024;15(3):e00672-e00672. https://doi.org/10.14309/ctg.0000000000000672
Eluri S, Book WM, Kodroff E, Strobel MJ, Gebhart JH, Jones PD, et al. Lack of Knowledge and Low Readiness for Healthcare Transition in Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. J Pediatr Gastroenterol Nutr. 2017;65(1):53-57. https://doi.org/10.1097/MPG.0000000000001415
UNC School of Medicine. Translations of the STARx Questionnaire [Internet]. UNC [consultado el 4 de agosto de 2024]. Disponible en: https://www.med.unc.edu/transition/transition-tools/trxansition-scale/versions-of-the-starx-questionnaire/
Dellon ES, Jones PD, Martin NB, Kelly M, Kim SC, Freeman KL, et al. Health-care transition from pediatric to adult-focused gastroenterology in patients with eosinophilic esophagitis. Dis esophagus Off J Int Soc Dis Esophagus. 2013;26(1):7-13. https://doi.org/10.1111/j.1442-2050.2011.01315.x
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Revista colombiana de Gastroenterologia

Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

| Métricas do artigo | |
|---|---|
| Vistas abstratas | 1167 |
| Visualizações da cozinha | 1218 |
| Visualizações de PDF | 805 |
| Visualizações em HTML | 0 |
| Outras visualizações | 413 |














